메뉴 건너뛰기




Volumn 36, Issue 40, 2015, Pages 2729-2732

Protective overweight in cardiovascular disease: Moving from 'paradox' to 'paradigm'

Author keywords

[No Author keywords available]

Indexed keywords

BODY MASS; BODY WEIGHT; BODY WEIGHT MANAGEMENT; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CONFOUNDING VARIABLE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIET THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; EXERCISE; HUMAN; HYPERLIPOPROTEINEMIA; HYPERTENSION; LIFESTYLE MODIFICATION; OBESITY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; CARDIOVASCULAR DISEASES; FEMALE; MALE;

EID: 84948654631     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv414     Document Type: Review
Times cited : (50)

References (13)
  • 2
    • 84888028753 scopus 로고    scopus 로고
    • Cachexia vs obesity: Where is the real unmet clinical need?
    • von Haehling S, Anker SD. Cachexia vs obesity: where is the real unmet clinical need? J Cachexia Sarcopenia Muscle 2013;4:245-246.
    • (2013) J Cachexia Sarcopenia Muscle , vol.4 , pp. 245-246
    • Von Haehling, S.1    Anker, S.D.2
  • 5
    • 84906938046 scopus 로고    scopus 로고
    • Critical appraisal of the obesity paradox in cardiovascular disease: How to manage patients with overweight in heart failure?
    • Doehner W. Critical appraisal of the obesity paradox in cardiovascular disease: how to manage patients with overweight in heart failure? Heart Fail Rev 2014;19:637-644.
    • (2014) Heart Fail Rev , vol.19 , pp. 637-644
    • Doehner, W.1
  • 6
    • 84948655369 scopus 로고    scopus 로고
    • Cardiovascular risk in relation to body mass index and use of evidence-based preventive medications in patients with or at risk of atherothrombosis
    • Hansel B, Roussel R, Elbez Y, Marre M, Krempf M, Ikeda Y, Eagle KA, Elisaf M, Bhatt DL, Steg PG; REACH Registry Investigators. Cardiovascular risk in relation to body mass index and use of evidence-based preventive medications in patients with or at risk of atherothrombosis. Eur Heart J 2015;36:2716-2728.
    • (2015) Eur Heart J , vol.36 , pp. 2716-2728
    • Hansel, B.1    Roussel, R.2    Elbez, Y.3    Marre, M.4    Krempf, M.5    Ikeda, Y.6    Eagle, K.A.7    Elisaf, M.8    Bhatt, D.L.9    Steg, P.G.10
  • 12
    • 84951557779 scopus 로고    scopus 로고
    • Prevalence, incidence, and clinical impact of sarcopenia: Facts, numbers, and epidemiology-update 2014
    • Morley JE, Anker SD, von Haehling S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014. J Cachexia Sarcopenia Muscle 2014;5:253-259.
    • (2014) J Cachexia Sarcopenia Muscle , vol.5 , pp. 253-259
    • Morley, J.E.1    Anker, S.D.2    Von Haehling, S.3
  • 13
    • 84908294192 scopus 로고    scopus 로고
    • Metabolic impairment in heart failure: The myocardial and systemic perspective
    • Doehner W, Frenneaux M, Anker SD. Metabolic impairment in heart failure: the myocardial and systemic perspective. J Am Coll Cardiol 2014;64:1388-1400.
    • (2014) J Am Coll Cardiol , vol.64 , pp. 1388-1400
    • Doehner, W.1    Frenneaux, M.2    Anker, S.D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.